// Auto-generated - do not edit
export const substanceName = "Deschloroketamine";
export const sources = [{"id":"protestkit","fileName":"PROTESTKIT - Deschloroketamine.json","displayName":"Protest Kit","size":8711},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Deschloroketamine.md","displayName":"PsychonautWiki","size":24602},{"id":"thedrugclassroom","fileName":"THEDRUGCLASSROOM - Deschloroketamine.md","displayName":"The Drug Classroom","size":12371},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Deschloroketamine.md","displayName":"TripSit Factsheets","size":488},{"id":"wikipedia","fileName":"WIKIPEDIA - Deschloroketamine.md","displayName":"Wikipedia","size":400}];
export const contents: Record<string, string> = {
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Deschloroketamine",
  "experiencesUrl": "https://www.reddit.com/search/?q=Deschloroketamine",
  "name": "Deschloroketamine",
  "aliases": [
    "2'-oxo-pcm",
    "2-oxo-pcm",
    "dck",
    "dxe",
    "o-pcm",
    "opcm"
  ],
  "aliasesStr": "2'-oxo-pcm,2-oxo-pcm,dck,dxe,o-pcm,opcm",
  "summary": "A novel analogue of Ketamine which is much more potent and has a longer duration.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Arylcyclohexylamines"
    ],
    "psychoactive": [
      "Dissociatives"
    ]
  },
  "toxicity": [
    "exact toxic dosage is unknown"
  ],
  "addictionPotential": "moderately addictive with a high potential for abuse",
  "tolerance": {
    "full": "develops with prolonged and repeated use",
    "half": "3 - 7 days",
    "zero": "1 - 2 weeks"
  },
  "crossTolerances": [
    "dissociative"
  ],
  "roas": [
    {
      "name": "Smoked",
      "dosage": [
        {
          "name": "Threshold",
          "value": "5 mg"
        },
        {
          "name": "Light",
          "value": "5 - 10 mg"
        },
        {
          "name": "Common",
          "value": "10 - 20 mg"
        },
        {
          "name": "Strong",
          "value": "20 - 40 mg"
        },
        {
          "name": "Heavy",
          "value": "40 mg +"
        }
      ],
      "duration": [
        {
          "name": "Total",
          "value": "30.0 - 90.0 minutes"
        }
      ]
    },
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "10 mg"
        },
        {
          "name": "Light",
          "value": "10 - 20 mg"
        },
        {
          "name": "Common",
          "value": "20 - 30 mg"
        },
        {
          "name": "Strong",
          "value": "30 - 50 mg"
        },
        {
          "name": "Heavy",
          "value": "50 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.17 - 0.5 hours"
        },
        {
          "name": "Come up",
          "value": "0.5 - 1.0 hours"
        },
        {
          "name": "Peak",
          "value": "1.5 - 2.5 hours"
        },
        {
          "name": "Offset",
          "value": "1.0 - 2.0 hours"
        },
        {
          "name": "Total",
          "value": "4.0 - 6.0 hours"
        },
        {
          "name": "After effects",
          "value": "3.0 - 24.0 hours"
        }
      ]
    },
    {
      "name": "Insufflated",
      "dosage": [
        {
          "name": "Threshold",
          "value": "5 mg"
        },
        {
          "name": "Light",
          "value": "10 - 15 mg"
        },
        {
          "name": "Common",
          "value": "15 - 25 mg"
        },
        {
          "name": "Strong",
          "value": "25 - 40 mg"
        },
        {
          "name": "Heavy",
          "value": "40 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.08 - 0.25 hours"
        },
        {
          "name": "Come up",
          "value": "0.5 - 1.0 hours"
        },
        {
          "name": "Peak",
          "value": "1.5 - 2.5 hours"
        },
        {
          "name": "Offset",
          "value": "1.0 - 2.0 hours"
        },
        {
          "name": "Total",
          "value": "3.0 - 6.0 hours"
        },
        {
          "name": "After effects",
          "value": "3.0 - 24.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Caution"
    },
    {
      "name": "Benzos",
      "status": "Caution"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Cocaine",
      "status": "Caution"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "DXM",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MAOIs",
      "status": "Caution"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MMC class",
      "status": "Unsafe"
    },
    {
      "name": "MXE",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Auditory hallucination, Auditory distortion, Geometry, Pattern recognition suppression, Synaesthesia, Double vision, Scenery slicing, Perspective distortion, Environmental cubism, Environmental orbism, Cognitive disconnection, Physical disconnection, Nausea, Dizziness, Spontaneous bodily sensations, Physical autonomy, Physical euphoria, Increased libido, Dream potentiation, Internal hallucination, Autonomous entity, Settings, sceneries, and landscapes, Time distortion, Déjà vu, Conceptual thinking, Scenarios and plots, Unity and interconnectedness, Cognitive euphoria, Visual disconnection, Thought deceleration, Memory suppression, Disinhibition, Tactile suppression, Sedation, Perception of bodily lightness, Motor control loss, Pain relief, Muscle relaxation, Anxiety suppression, Increased music appreciation, Existential self-realization, Creativity enhancement, Depersonalization, Compulsive redosing, Derealization, Amnesia, Visual acuity suppression, Decreased libido, Spatial disorientation, Optical sliding, Mania, Perspective hallucination, Immersion intensification, Auditory acuity suppression, Visual processing deceleration, Analysis depression, Orgasm depression, Increased introspection",
  "categorized_effects": {
    "Physical effects": [
      "Nausea",
      "Dizziness",
      "Physical euphoria",
      "Sedation",
      "Motor control loss",
      "Pain relief",
      "Muscle relaxation"
    ],
    "Mental effects": [
      "Pattern recognition suppression",
      "Cognitive disconnection",
      "Physical disconnection",
      "Dream potentiation",
      "Internal hallucination",
      "Time distortion",
      "Déjà vu",
      "Conceptual thinking",
      "Unity and interconnectedness",
      "Cognitive euphoria",
      "Thought deceleration",
      "Memory suppression",
      "Disinhibition",
      "Anxiety suppression",
      "Increased music appreciation",
      "Existential self-realization",
      "Creativity enhancement",
      "Depersonalization",
      "Derealization",
      "Amnesia",
      "Spatial disorientation",
      "Mania",
      "Immersion intensification",
      "Analysis depression",
      "Increased introspection"
    ],
    "Sensory effects": [
      "Auditory hallucination",
      "Auditory distortion",
      "Synaesthesia",
      "Double vision",
      "Scenery slicing",
      "Perspective distortion",
      "Spontaneous bodily sensations",
      "Increased libido",
      "Visual disconnection",
      "Tactile suppression",
      "Perception of bodily lightness",
      "Visual acuity suppression",
      "Decreased libido",
      "Optical sliding",
      "Perspective hallucination",
      "Auditory acuity suppression",
      "Visual processing deceleration",
      "Orgasm depression"
    ],
    "Uncategorized effects": [
      "Geometry",
      "Environmental cubism",
      "Environmental orbism",
      "Physical autonomy",
      "Autonomous entity",
      "Settings",
      "sceneries",
      "and landscapes",
      "Scenarios and plots",
      "Compulsive redosing"
    ]
  }
}`,
  "psychonautwiki": `# Deschloroketamine
*Source: https://psychonautwiki.org/wiki/Deschloroketamine*

## Dosage & Duration

### Smoked

**Dosage:**
- Threshold: 5 mg
- Light: 5 - 10 mg
- Common: 10 - 20 mg
- Strong: 20 - 40 mg
- Heavy: 40 mg +

**Duration:**
- Total: 30 - 90 minutes

### Oral

**Dosage:**
- Threshold: 10 mg
- Light: 10 - 20 mg
- Common: 20 - 30 mg
- Strong: 30 - 50 mg
- Heavy: 50 mg +

**Duration:**
- Total: 4 - 6 hours
- Onset: 10 - 30 minutes
- Come up: 30 - 60 minutes
- Peak: 1.5 - 2.5 hours
- Offset: 1 - 2 hours
- After effects: 3 - 24 hours

### Insufflated

**Dosage:**
- Threshold: 5 mg
- Light: 10 - 15 mg
- Common: 15 - 25 mg
- Strong: 25 - 40 mg
- Heavy: 40 mg +

**Duration:**
- Total: 3 - 6 hours
- Onset: 5 - 15 minutes
- Come up: 30 - 60 minutes
- Peak: 1.5 - 2.5 hours
- Offset: 1 - 2 hours
- After effects: 3 - 24 hours

**2'-Oxo-PCM** (also known as **deschloroketamine** , **O-PCM** , **DXE** , and **DCK** ) is a lesser-known novel [dissociative](https://psychonautwiki.org/wiki/Dissociative) substance of the [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) class that produces [dissociative](https://psychonautwiki.org/wiki/Dissociative) , [anesthetic](https://psychonautwiki.org/wiki/Pain_relief) and [hallucinogenic](https://psychonautwiki.org/wiki/Hallucinogenic) effects when [administered](https://psychonautwiki.org/wiki/Routes_of_administration) .

Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it is possible that its prolonged use could potentially pose a serious threat to one's health and immune system, which along with bladder and urinary tract problems is why misuse of this substance is highly discouraged. Ketamine has been found to have similar properties.

DCK has become easily accessible through online [research chemical](https://psychonautwiki.org/wiki/Research_chemical) vendors where it is being sold as a [designer drug](https://psychonautwiki.org/wiki/Designer_drug) .

Very little data exists about the pharmacological properties, metabolism, and toxicity of DCK, and it has a very brief history of human usage. It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) if choosing to use this substance.

## Chemistry

Deschloroketamine, or 2-Phenyl-2-(methylamino)cyclohexanone, is classed as an [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) drug. Arylcyclohexylamine drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group. Descholoroketamine contains a phenyl ring bonded to a cyclohexane ring substituted with an oxo group (cyclohexanone). An amino methyl chain (-N-CH 3 ) is bound to the adjacent alpha carbon (R 2 ) of the cyclohexanone ring.

Descholoroketamine is a chiral molecule and is often produced as a racemate. Des- is a prefix used in chemistry to denote the absence of a functional group (in this case "chloro") hence deschloroketamine is named for lacking a chlorine substitution on its phenyl ring, which is found in ketamine.

## Pharmacology

Due to the lack of research regarding the substance, all discussion regarding its pharmacology is purely based on its structure and subjective effect similarities to other [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) [dissociatives](https://psychonautwiki.org/wiki/Dissociative) such as [3-MeO-PCP](https://psychonautwiki.org/wiki/3-MeO-PCP) , [PCP](https://psychonautwiki.org/wiki/PCP) and [MXE](https://psychonautwiki.org/wiki/MXE) . With this in mind, DCK is thought to act as an [NMDA receptor antagonist](https://psychonautwiki.org/wiki/NMDA_receptor_antagonist) . NMDA receptors, a type of [glutamate](https://psychonautwiki.org/wiki/Glutamate) receptor, allow for excitatory electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives inactivate the NMDA receptors by blocking them. This disconnection of neurons leads to the general loss of bodily sensation, motor coordination, memory recall and eventually this substance's equivalent of the “ [k-hole](https://psychonautwiki.org/wiki/Visual_disconnection#Holes.2C_spaces_and_voids) .”

## Subjective effects

In terms of its subjective effects, this compound feels closer to that of [ketamine](https://psychonautwiki.org/wiki/Ketamine) and [MXE](https://psychonautwiki.org/wiki/MXE) than more stimulating, non-immobilizing compounds of the same class such as [3-MeO-PCP](https://psychonautwiki.org/wiki/3-MeO-PCP) , [O-PCE](https://psychonautwiki.org/wiki/O-PCE) and [PCP](https://psychonautwiki.org/wiki/PCP) . It has therefore come to be considered a more suitable ketamine substitute than many other popular [arylcyclohexylamines](https://psychonautwiki.org/wiki/Arylcyclohexylamines) currently available on the research chemicals market, although users are advised to exercise extreme caution due to the health risks it may pose if it does possess its speculated antibacterial properties.

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Pain relief](https://psychonautwiki.org/wiki/Pain_relief)**
- **[Spontaneous physical sensations](https://psychonautwiki.org/wiki/Spontaneous_physical_sensations)**
- **[Motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss)**
- **[Muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation)**
- **[Nausea](https://psychonautwiki.org/wiki/Nausea)**
- **[Sedation](https://psychonautwiki.org/wiki/Sedation)**
- **[Perception of bodily lightness](https://psychonautwiki.org/wiki/Perception_of_bodily_lightness)**
- **[Physical autonomy](https://psychonautwiki.org/wiki/Physical_autonomy)** - This is reported to be especially present at low doses and to decrease as the dose increases. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Physical euphoria](https://psychonautwiki.org/wiki/Physical_euphoria)** - This is reported to be present even at low doses. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Spatial disorientation](https://psychonautwiki.org/wiki/Spatial_disorientation)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)**
- **[Tactile suppression](https://psychonautwiki.org/wiki/Tactile_suppression)**
- **[Optical sliding](https://psychonautwiki.org/wiki/Optical_sliding)**
- **[Decreased libido](https://psychonautwiki.org/wiki/Decreased_libido)** - This is not experienced in all environments, as [Increased libido](https://psychonautwiki.org/wiki/Increased_libido) may also be experienced.
- **[Orgasm suppression](https://psychonautwiki.org/wiki/Orgasm_suppression)** - Orgasm enhancement can also be present, even at higher doses. ### Disconnective effects
 
- - **[Tactile disconnection](https://psychonautwiki.org/wiki/Tactile_disconnection)**
- **[Visual disconnection](https://psychonautwiki.org/wiki/Visual_disconnection)** - This eventually results in DCK's equivalent of the famous " [k-hole](https://en.wikipedia.org/wiki/K-hole) " or, more specifically, *[holes, spaces and voids](https://psychonautwiki.org/wiki/Visual_disconnection#Holes.2C_spaces_and_voids)* alongside of *[structures](https://psychonautwiki.org/wiki/Visual_disconnection#Structures)* .
- **[Consciousness disconnection](https://psychonautwiki.org/wiki/Consciousness_disconnection)** ### Auditory effects
 
- - **[Suppression](https://psychonautwiki.org/wiki/Auditory_suppression)**
- **[Distortions](https://psychonautwiki.org/wiki/Auditory_distortion)**
- **[Hallucinations](https://psychonautwiki.org/wiki/Auditory_hallucinations)** ### Multi-sensory effects
 
- - **[Synaesthesia](https://psychonautwiki.org/wiki/Synaesthesia)** ### Transpersonal effects
 
- - **[Existential self-realization](https://psychonautwiki.org/wiki/Existential_self-realization)**
- **[Unity and interconnectedness](https://psychonautwiki.org/wiki/Unity_and_interconnectedness)** ### Cognitive effects
 
- - **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)**
- **[Disinhibition](https://psychonautwiki.org/wiki/Disinhibition)**
- **[Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing)**
- **[Conceptual thinking](https://psychonautwiki.org/wiki/Conceptual_thinking)**
- **[Creativity enhancement](https://psychonautwiki.org/wiki/Creativity_enhancement)**
- **[Déjà vu](https://psychonautwiki.org/wiki/D%C3%A9j%C3%A0_vu)**
- **[Depersonalization](https://psychonautwiki.org/wiki/Depersonalization)**
- **[Derealization](https://psychonautwiki.org/wiki/Derealization)**
- **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)**
- **[Memory suppression](https://psychonautwiki.org/wiki/Memory_suppression)** 
- **[Ego death](https://psychonautwiki.org/wiki/Ego_death)**
- **[Amnesia](https://psychonautwiki.org/wiki/Amnesia)**
- **[Immersion enhancement](https://psychonautwiki.org/wiki/Immersion_enhancement)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)**
- **[Analysis suppression](https://psychonautwiki.org/wiki/Analysis_suppression)**
- **[Introspection](https://psychonautwiki.org/wiki/Introspection)**
- **[Mania](https://psychonautwiki.org/wiki/Mania)**
- **[Time distortion](https://psychonautwiki.org/wiki/Time_distortion)**
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)** ### Visual effects
 
- #### Suppression
 
- **[Double vision](https://psychonautwiki.org/wiki/Double_vision)**
- **[Frame rate suppression](https://psychonautwiki.org/wiki/Frame_rate_suppression)**
- **[Pattern recognition suppression](https://psychonautwiki.org/wiki/Pattern_recognition_suppression)**
- **[Visual acuity suppression](https://psychonautwiki.org/wiki/Visual_acuity_suppression)**
 
#### Distortions
 
- **[Perspective distortions](https://psychonautwiki.org/wiki/Perspective_distortions)**
- **[Environmental cubism](https://psychonautwiki.org/wiki/Environmental_cubism)**
- **[Environmental orbism](https://psychonautwiki.org/wiki/Environmental_orbism)**
- **[Scenery slicing](https://psychonautwiki.org/wiki/Scenery_slicing)**
 
#### Geometry
 
#### Hallucinatory states
 
- **[Internal hallucination](https://psychonautwiki.org/wiki/Internal_hallucination)** ( *[autonomous entities](https://psychonautwiki.org/wiki/Autonomous_entities)* ; *[settings, sceneries, and landscapes](https://psychonautwiki.org/wiki/Settings,_sceneries,_and_landscapes)* ; *[perspective hallucinations](https://psychonautwiki.org/wiki/Perspective_hallucinations)* and *[scenarios and plots](https://psychonautwiki.org/wiki/Scenarios_and_plots)* )
### Experience reports

There are currently anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) .

- [Experience:25mg Deschloroketamine - My first time orally dosing DCK](https://psychonautwiki.org/wiki/Experience:25mg_Deschloroketamine_-_My_first_time_orally_dosing_DCK)

Additional experience reports can be found here:

- [Erowid Experience Vaults: Deschloroketamine](https://erowid.org/experiences/subs/exp_Deschloroketamine.shtml)

## Toxicity and harm potential

The toxicity and long-term health effects of recreational DCK use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because DCK has very little history of human usage. Anecdotal evidence from people who have tried DCK within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). [Independent research](https://www.google.com/) should always be done to ensure that a combination of two or more substances is safe before consumption.

As DCK has been speculated to have antibacterial properties, its prolonged use could potentially pose a serious threat to one's health and immune system.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this substance.

### Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of DCK can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [withdrawal effects](https://psychonautwiki.org/wiki/Withdrawal_effects) may occur if a person suddenly stops their usage.

Tolerance to many of the effects of DCK develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). DCK presents cross-tolerance with all [dissociatives](https://psychonautwiki.org/wiki/Dissociative) , meaning that after the consumption of DCK all [dissociatives](https://psychonautwiki.org/wiki/Dissociative) will have a reduced effect.

### Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, DCK seems to exhibit almost identical bladder and urinary tract problems to those found within [ketamine](https://psychonautwiki.org/wiki/Ketamine) but to a lesser extent. This is suspected to be because DCK is more potent than ketamine, meaning that less of the drug needs to be consumed to produce analogous effects. Symptoms of ketamine-induced cystitis can become extremely serious and include:

- **Urinary frequency** - Urinary frequency is the need to empty the bladder every few minutes.
- **Urinary urgency** - This can be described as a sudden, compelling need to urinate.
- **Urinary pressure** - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
- **Pelvic and bladder pain** - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
- **Hematuria** - Hematuria is visible blood in the urine.
- **Incontinence** - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using DCK on a daily or even weekly basis and manually limiting one's usage of the substance.

### Dangerous interactions

***Warning:*** *Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).*

*Always conduct independent research (e.g. [Google](https://www.google.com) , [DuckDuckGo](https://www.duckduckgo.com) , [PubMed](https://pubmed.ncbi.nlm.nih.gov/) ) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from [TripSit](https://combo.tripsit.me) .*

- **Stimulants** - Both stimulants and dissociatives carry the risk of adverse psychological reactions like [anxiety](https://psychonautwiki.org/wiki/Anxiety) , [mania](https://psychonautwiki.org/wiki/Mania) , [delusions](https://psychonautwiki.org/wiki/Delusions) and [psychosis](https://psychonautwiki.org/wiki/Psychosis) and these risks are exacerbated when the two substances are combined.
- **Depressants** - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If [nausea](https://psychonautwiki.org/wiki/Nausea) or vomiting occurs, users should attempt to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.

## Legal status

- **Italy:** Deschloroketamine is illegal in Italy.
- **Latvia:** Deschloroketamine is illegal in Latvia.
- **Germany:** Deschloroketamine is controlled under the NpSG ( *New Psychoactive Substances Act* ) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- **Switzerland:** Deschloroketamine is a controlled substance specifically named under Verzeichnis E.
- **United Kingdom:** Deschloroketamine is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 2-Amino-2-phenylcyclohexanone, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
- **Czech Republic:** Deschloroketamine is legal in the Czech Republic.
- **Austria:** Deschloroketamine is illegal in Austria under the NPSV (Neue-Psychoaktive-Substanzen-Verordnung).
- **Netherlands:** Deschloroketamine is legal at least until a plenary hearing scheduled for January 21, 2025.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Designer drug](https://psychonautwiki.org/wiki/Designer_drug)
- [Dissociative](https://psychonautwiki.org/wiki/Dissociative)
- [O-PCE](https://psychonautwiki.org/wiki/O-PCE)
- [Ketamine](https://psychonautwiki.org/wiki/Ketamine)
- [MXE](https://psychonautwiki.org/wiki/MXE)

# External links

- [Deschloroketamine (Wikipedia)](https://en.wikipedia.org/wiki/Deschloroketamine)
- [Deschloroketamine (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=985)

### Discussion

- [The Big & Dandy Deschloroketamine Thread (Bluelight)](http://www.bluelight.org/vb/threads/766127-The-Small-amp-Handy-Deschloroketamine-Thread)

## Literature

- Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. [https://doi.org/10.1002/dta.1620](https://doi.org/10.1002/dta.1620)

## References
1. ↑ 1.0 1.1 Robins, E. G., Zhao, Y., Khan, I., Wilson, A., Luthra, S. K., Rstad, E. (1 March 2010). "Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET".*Bioorganic & Medicinal Chemistry Letters*.**20**(5): 1749–1751.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.bmcl.2010.01.052](//doi.org/10.1016%2Fj.bmcl.2010.01.052).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1464-3405](//www.worldcat.org/issn/1464-3405).
2. ↑ 2.0 2.1 Stevens, C. L.,[Aminoketones and methods for their production](https://patents.google.com/patent/US3254124/en)
3. ↑ Preiss, D., Tatar, A.,[Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, virus or protozoan infections as well as for immunomodulation](https://patents.google.com/patent/US5811464/en)
4. ↑ Gocmen, S., Buyukkocak, U., Caglayan, O. (2008). "In vitro investigation of the antibacterial effect of ketamine".*Upsala Journal of Medical Sciences*.**113**(1): 39–46.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.3109/2000-1967-211](//doi.org/10.3109%2F2000-1967-211).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[2000-1967](//www.worldcat.org/issn/2000-1967).
5. ↑ Frison, G., Zamengo, L., Zancanaro, F., Tisato, F., Traldi, P. (15 January 2016). "Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance".*Rapid communications in mass spectrometry: RCM*.**30**(1): 151–160.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/rcm.7425](//doi.org/10.1002%2Frcm.7425).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1097-0231](//www.worldcat.org/issn/1097-0231).
6. ↑ Alert: descloroketamina sold as ketamine in Barcelona | [http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html](http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html)
7. ↑ Villalba, J. (2015),[Los efectos desconocidos de la sequía de ketamina](https://www.vice.com/es/article/9b7yvp/los-efectos-desconocidos-de-la-sequia-de-ketamina-719)
8. ↑ [http://www.salute.gov.it/imgs/C_17_pagineAree_3729_0_file.pdf](http://www.salute.gov.it/imgs/C_17_pagineAree_3729_0_file.pdf)
9. ↑ Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | [http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc](http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc)
10. ↑ ["Anlage NpSG"](https://www.gesetze-im-internet.de/npsg/anlage.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
11. ↑ ["Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes"](http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf)(PDF).*Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27*(in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
12. ↑ ["§ 4 NpSG"](https://www.gesetze-im-internet.de/npsg/__4.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
13. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
14. ↑ [The Misuse of Drugs Act 1971 (Amendment) Order 2013](https://www.legislation.gov.uk/uksi/2013/239/introduction/made)
15. ↑ info@aion.cz, A. C.-,[463/2013 Sb. Nařízení vlády o seznamech návykových látek](https://www.zakonyprolidi.cz/cs/2013-463)
16. ↑ [RIS - Neue-Psychoaktive-Substanzen-Verordnung - Bundesrecht konsolidiert, Fassung vom 21.07.2022](https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007642)
17. ↑ [36.159 Tegengaan productie en handel in nieuwe psychoactieve stoffen](https://www.eerstekamer.nl/infodossier/tegengaan_productie_en_handel_in)NewPP limit report Cached time: 20251218075313 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.079 seconds CPU time usage: 0.399 seconds Real time usage: 0.767 seconds Preprocessor visited node count: 2221/1000000 Post‐expand include size: 154338/2097152 bytes Template argument size: 15529/2097152 bytes Highest expansion depth: 22/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 18330/5000000 bytes Lua time usage: 0.250/7 seconds Lua virtual size: 8.16 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 33Transclusion expansion time report (%,ms,calls,template) 100.00% 611.242 1 -total 20.78% 127.026 3 Template:Cite_journal 19.53% 119.405 1 Template:Effects/base 18.90% 115.496 1 Template:Effect_list 18.28% 111.746 2 Template:Effect_column 14.72% 89.977 7 Template:Citation 14.23% 86.963 1 Template:Effects/physical 13.79% 84.290 7 Template:Effect_panel 13.11% 80.109 2 Template:Citation_needed 13.04% 79.681 1 Template:SubstanceBox/Deschloroketamine`,
  "thedrugclassroom": `# Deschloroketamine
*Source: https://thedrugclassroom.com/video/deschloroketamine/*

Deschloroketamine is a dissociative research chemical in the arylcyclohexylamine class. It’s very close to ketamine with its structure and it’s closer to ketamine and MXE than to PCP-like dissociatives with its effects.

It might have some antimicrobial properties, but those have only been minimally investigated. If those properties are real, they may provide another reason to limit your frequency of exposure.

The drug is more potent than ketamine and lasts longer.

---

Deschloroketamine = AC1L935Y; DCK; 2′-Oxo-PCM; O-PCM; 2-Phenyl-2-(methylamino)cyclohexanone

PubChem: 437168

Molecular formula: C13H17NO

Molecular weight: 203.285 g/mol

IUPAC: 2-(methylamino)-2-phenylcyclohexan-1-one

---

## Dose

#### Oral (tentative)

Light: 5 – 15 mg

Common: 15 – 30 mg

Strong: 30 – 50 mg

There are varying reports regarding the drug’s dosing. Some people find it’s most effective at 50 or 60+ mg, but it’s best to use lower doses, at least initially.

#### Intranasal (tentative)

Light: 5 – 15 mg

Common: 15 – 25 mg

Strong: 25 – 40 mg

---

## Timeline

#### Oral (tentative)

Total: 4 -6 hours

Onset: 00:30 – 01:00

#### Intranasal (tentative)

Total: 3 – 6 hours

Onset: 00:05 – 00:15

---

## Experience Reports

[Erowid](https://erowid.org/experiences/subs/exp_Deschloroketamine.shtml)

---

---

## Effects

#### Positive

- Anxiolysis
- Dissociation
- Sedation
- Mood improvement
- Introspection
- CEVs and OEVs
- Physical euphoria
- Music enhancement

#### Negative

- Memory impairment
- Motor control impairment
- Nausea
- Dizziness
- Confusion
- Insomnia
- Drowsiness

Compared to other dissociatives, it’s typically placed between ketamine and PCP, but is often said to be closer to ketamine and MXE-like dissociatives. It lasts much longer than ketamine, which some people find is a negative quality.

It appears to typically offer relatively tame mental effects and a lower risk of mania than certain dissociatives.

People tend to either like the effects or find them boring. In the “boring” reports, users say it doesn’t offer much beyond basic dissociation and sedation. It’s pretty uncommon to have severely negative experiences.

#### Visuals

At common doses, blurriness, double vision, and seeing things as closer or farther away is common.

The CEVs at common doses can include colors and basic patterns.

#### Common doses

DCK offers a progressive detachment from your body in a dose-dependent manner. Initially, your limbs will feel different when moving and your ability to engage in fluid, quick movements is impaired. There may be a feeling of floatiness.

A general sedative effect is common, though not to the point of falling asleep at normal doses.

The feelings arising from your body can change. You may notice numbness, especially in your extremities, and tactile perception can be blunted. Another common element is a pleasurable feeling of warmth and fuzziness.

At least to a certain degree the effects are akin to non-drug psychological “dissociation.” This is a state in which the person feels less identified with their body and mental activity. They’re acting more as an “observer” than the subject.

It can be hard to think and maintain a normal thought stream, which can be quite impairing. This can lead to a meditative/calm mindset, with lower distractions both externally and internally. Some people find it’s quite a lucid experience, but there are also reports of confusion and major cognitive impairment that leaves people feeling unintelligent for hours.

DCK sometimes offers a psychedelic-like feeling of profoundness and importance, but this isn’t the most typical response.

Difficulty speaking and otherwise communicating is fairly common.

#### Common+ doses

With a sufficient level of dissociation, a sedated and highly disconnected state can arise, often featuring more notable CEVs and OEVs. The OEVs can include somewhat psychedelic-like visuals, such as morphing and melting.

Internally, people can enter states where they’re mostly or entirely oblivious to the outside world. During this time they may experience dream-like sequences or hallucinatory landscapes/environments. Sometimes people even have dream-like scenarios that play out with eyes open.

While these “hole” experiences have been reported with DCK, they might be harder to reach vs. with ketamine.

There can be significant time distortion, especially during a “hole” experience. The “hole,” when obtained, is sometimes described as MXE-like. It can include colors and various dream-like worlds.

Memory is often impaired, so even remembering the entire experience or the hole is difficult.

Your body can feel like it’s distorting, typically in a pleasurable/interesting way.

#### After effects

Some people report depression or cognitive impairment for up to a day after the experience is over. But, like with other dissociatives, antidepressant effects are sometimes noted for a week or so.

---

## Chemistry & Pharmacology

#### Chemistry

Deschloroketamine is in the arylcyclohexylamine class. It only differs from ketamine in that a chlorine substitution has been removed.

#### Pharmacology

Though we lack pharmacology studies, it almost certainly operates as an NMDA antagonist. Other potential mechanisms have yet to be elucidated.

**Antimicrobial**

A couple patents from the same group in Germany (Detlef Preiss and Akos Tatar) outlined the alleged antimicrobial properties of DCK. Those patents were published around the year 2000 and nothing else has happened with the info since then. No further research has been conducted to formally test DCK’s antimicrobial properties.

Because the burden of proof for patents is low, properties described within them shouldn’t be taken as fact.

There’s also some evidence that ketamine has antimicrobial properties as well, though it’s not clear if they’re present at concentrations relevant to humans.

Patents

Patent 6083992

- From: Detlef Preiss and Akos Tatar
- Found DCK was “effective against a number of bacterial diseases.”
- Patient 
- Bad state of health; HIV-infected for over 10 years
- Suffering from unspecified mycoplasmal infection and perimyocarditis as well as neuropathy
- Given 2 mg DCK twice per week for 6 weeks
- Condition improved significantly; gained weight and had no other infections
- Then repeat attack of infections after 9 months, including Plaut’s angina, candidiasis, cytomegalic disease, and lip herpes. 
- Again given 2 mg DCK twice per week
- Recovered completely from all infections during the therapy course.
- Claim: 
- 1 – A method of treating a patient having a bacterial infection using DCK or its physiologically tolerable salts.
- 2 – A method of treating a patient where the infection is a mycoplasmal infection.

Patent 5811464

- From: Detlef Preiss and Akos Tatar
- Found DCK “is effective in a great number of bacterial, fungal, virus and protozoan diseases, and in immunomodulation.”
- Examples 
- 1 – Toxoplasmosis 
- Patient showed multifocal toxoplasmosis on CT scan
- Given 2 mg DCK twice a week for 8 weeks; then no medication for 4 weeks; then same DCK regimen for 2 weeks
- General condition improved noticeably within 1 month
- Foci of toxoplasmosis showed major improvement after treatment; indicating clear or even complete regression of the foci.
- 2 – Cytomegalovirus diseases 
- Patient with fever
- Generalized swelling of a lymph node and CMB-related conjunctivitis (serum test)
- Given 2 mg DCK on first, third, fourth, and fifth day
- Patient free from fever on 3rd day, swelling in lymph node gone on 4th day, and conjunctivitis gone from 6th day.
- Patient returned to a good state of health.
- 3 – Various herpetic infections 
- Various groups with lip herpes, genital herpes, herpes zoster, and herpes simplex
- Given 2 mg DCK daily for 4-5 days
- Diseases cured more rapidly to a statistically significant degree in those with treatment.
- 4 – Treatment of HIV diseases 
- Same case as from the Patent 6083992
- Claim: 
- Method of treating immunovirus caused disease, namely, AIDS or ARC, and for the modulation of the immune responses of said patient
- Method of treating herpetic infections

---

## History

#### 1966

A patent from Calvin Stevens at Parke-Davis in Michigan described the preparation of deschloroketamine.

#### 1998 – 2000

A couple patents from a group in Germany were published. They described the alleged antimicrobial properties of the substance.

DCK was allegedly capable of significantly benefiting people suffering from bacterial and other kinds of infections.

#### 2015

The EMCDDA received its first report of DCK’s presence through the EU’s Early Warning System. The report came from the UK in March 2015.

#### 2015 onward

Most experience reports have appeared online post-2015.

#### 2015 – 2016

(Frison, 2016) – Reported on the analysis of seized drugs in Italy. 102 envelopes (31 green, 20 pink, and 51 blue) were said to contain ketamine in powder form. Upon analysis, it was determined all of the green and blue envelopes were deschloroketamine, while the pink envelopes were methoxetamine.

#### 2016

(Hout, 2016) – Showed the presence of DCK on AlphaBay and Valhalla, two dark net markets, during the second quarter of 2016.

#### 2016

(Head, 2017) – Based on data from the DEA’s laboratory system, DCK was seized at least 8 times in the US during 2016.

---

## Legal Status

#### US (as of July 2017)

Uncontrolled

#### Other (list may not be complete)

Controlled in Canada (general ban), Latvia, and the UK (general ban).

---

## Safety

The safety of deschloroketamine isn’t known, largely due to it being a research chemical. It’s best to use common doses, infrequently, and without combinations.

**Overdose**

Using too much can result in unconsciousness, which comes with risks like vomit aspiration. The impaired, sedated state it provides can also be dangerous due to the potential for falls and other accidents.

**Urinary tract**

It could come with some of the same chronic use concerns as ketamine, meaning problems along the urinary tract that result in pain, increased urinary frequency, and other issues. Avoiding daily or near daily high-dose use can effectively prevent these potential effects.

**Psychological**

Some people find they’re more depressed and prone to emotional fluctuation after using dissociatives like DCK. If you notice this, it’s best to avoid the drug.

Acutely, it could also raise the chance of mania and hypomania, along with confusion.

**Antimicrobial**

Though these properties could potentially exist, they don’t appear to be a major concern with reasonable levels of low-frequency use. Among the possible chronic use concerns would be a disruption of the gut microbiome, but we don’t even know how real the antimicrobial properties are.

**Risky combinations (list may not be complete)**

- Other depressants, including ethanol, benzodiazepines, and opioids.
- MAOIs
- Tramadol

---

## Test Results

---

## References

**(2017)** [New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.](https://www.ncbi.nlm.nih.gov/pubmed/28027812)

**(2016)** [Characterization of the Designer Drug Deschloroketamine (2-Methylamino-2-Phenylcyclohexanone) by Gas Chromatography/Mass Spectrometry, Liquid Chromatography/High-Resolution Mass Spectrometry, Multistage Mass Spectrometry, and Nuclear Magnetic Resonance](https://www.ncbi.nlm.nih.gov/labs/articles/26661982/)

**(2016)** [EMCDDA–Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA](http://www.emcdda.europa.eu/publications/implementation-reports/2015)

**(2000)** [Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial infections](https://www.google.com/patents/US6083992)

**(2000)** [Use of 2-methylamino-2-phenylcyclohexanone for the treatment of protozoan infections](https://www.google.com/patents/US6020381)

**(1999)** [Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, virus or protozoan infections as well as for immunomodulation](https://www.google.ch/patents/CA2138447C?cl=en&hl=de)

**(1966)** [Aminoketones and methods for their production](https://www.google.com/patents/US3254124)
`,
  "tripsit-factsheets": `# Deschloroketamine
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/deschloroketamine*

## Classification
- **Categories:** dissociative, research-chemical, habit-forming, tentative
- **Also known as:** 2'-oxo-pcm, dxe, dck, o-pcm, opcm, 2-oxo-pcm

## Dosage

### Oral
- **Common:** 15-25mg
- **Heavy:** 40+mg.
- **Light:** 5-15mg
- **Strong:** 25-40mg

## Duration
- **Onset:** {'_unit': 'minutes', 'Insufflated': '2-20'}
- **Duration:** 3-6 hours
- **After Effects:** 1-8 hours
`,
  "wikipedia": `# Deschloroketamine
*Source: https://en.wikipedia.org/wiki/Deschloroketamine*

Deschloroketamine (DXE, DCK, 2'-Oxo-PCM) is a dissociative anesthetic that has been sold online as a designer drug. It has also been proposed for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation at doses of 2 mg per day.

## Legal status

Deschloroketamine is illegal in Latvia.
`,
};
